MX2019002932A - Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. - Google Patents
Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.Info
- Publication number
- MX2019002932A MX2019002932A MX2019002932A MX2019002932A MX2019002932A MX 2019002932 A MX2019002932 A MX 2019002932A MX 2019002932 A MX2019002932 A MX 2019002932A MX 2019002932 A MX2019002932 A MX 2019002932A MX 2019002932 A MX2019002932 A MX 2019002932A
- Authority
- MX
- Mexico
- Prior art keywords
- activation system
- contact activation
- diseases associated
- protein biomarkers
- contact
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395712P | 2016-09-16 | 2016-09-16 | |
| US201762518492P | 2017-06-12 | 2017-06-12 | |
| PCT/US2017/051749 WO2018053244A1 (en) | 2016-09-16 | 2017-09-15 | Protein biomarkers for diseases associated with the contact activation system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002932A true MX2019002932A (es) | 2019-07-15 |
Family
ID=59974881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002932A MX2019002932A (es) | 2016-09-16 | 2017-09-15 | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
| MX2024009782A MX2024009782A (es) | 2016-09-16 | 2019-03-13 | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009782A MX2024009782A (es) | 2016-09-16 | 2019-03-13 | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11815516B2 (https=) |
| EP (1) | EP3513196B1 (https=) |
| JP (4) | JP7225089B2 (https=) |
| KR (3) | KR102806918B1 (https=) |
| CN (2) | CN109716138B (https=) |
| AU (3) | AU2017325983B2 (https=) |
| BR (1) | BR112019005179A2 (https=) |
| CA (1) | CA3037154A1 (https=) |
| CO (1) | CO2019002599A2 (https=) |
| IL (2) | IL265195B2 (https=) |
| MX (2) | MX2019002932A (https=) |
| WO (1) | WO2018053244A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017325986B2 (en) | 2016-09-16 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| CN113092769A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液补体c4-a及其多肽片段在过敏性疾病中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US7399837B2 (en) * | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| JP2001174463A (ja) * | 1999-12-17 | 2001-06-29 | Hsp Research Institute Inc | 自己免疫疾患又は腫瘍の診断方法 |
| AU2001274888A1 (en) * | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| JP4399593B2 (ja) * | 2004-04-01 | 2010-01-20 | 国立大学法人 千葉大学 | インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット |
| EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| EP2500031A3 (en) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions and Methods for Treating Vascular Permeability |
| GB2428240A (en) * | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
| WO2007059966A1 (en) * | 2005-11-23 | 2007-05-31 | Georg Dewald | Detection and treatment of drug associated angioedema |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US20090104605A1 (en) * | 2006-12-14 | 2009-04-23 | Gary Siuzdak | Diagnosis of sepsis |
| US20110159011A1 (en) | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| US8883153B2 (en) * | 2009-03-27 | 2014-11-11 | The Research for The State University of New York | Methods for preventing and treating angioedema |
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| US9102942B2 (en) * | 2010-02-04 | 2015-08-11 | EWHA University—Industry Collaboration Foundation | Pharmaceutical composition for inhibiting abnormal proliferation of cells |
| JP2011226882A (ja) * | 2010-04-19 | 2011-11-10 | Kitasato Institute | 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| WO2012170947A2 (en) * | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| US20130102486A1 (en) * | 2011-10-20 | 2013-04-25 | The Board Of Trustees Of The Leland Stanford Junior University | Perp as a prognostic and diagnostic marker for dysplasia and cancer |
| EP2946206B1 (en) * | 2013-01-20 | 2019-01-09 | Dyax Corp. | Evaluation, assays and treatment of pkal-mediated disorders |
| WO2014113712A1 (en) * | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| JP6757252B2 (ja) * | 2013-10-21 | 2020-09-16 | ダイアックス コーポレーション | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| CA2927695C (en) * | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| AU2015209481C1 (en) * | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| EP3132053B1 (en) * | 2014-04-15 | 2020-09-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Differential diagnosis of eczema and psoriasis |
| EA201990730A1 (ru) | 2016-09-16 | 2019-08-30 | Дайэкс Корп. | Рнк-биомаркеры для наследственного ангионевротического отека |
| AU2017325986B2 (en) | 2016-09-16 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
-
2017
- 2017-09-15 KR KR1020237009552A patent/KR102806918B1/ko active Active
- 2017-09-15 CN CN201780057056.2A patent/CN109716138B/zh active Active
- 2017-09-15 EP EP17777136.7A patent/EP3513196B1/en active Active
- 2017-09-15 JP JP2019514252A patent/JP7225089B2/ja active Active
- 2017-09-15 CA CA3037154A patent/CA3037154A1/en active Pending
- 2017-09-15 IL IL265195A patent/IL265195B2/en unknown
- 2017-09-15 US US16/333,155 patent/US11815516B2/en active Active
- 2017-09-15 IL IL315799A patent/IL315799A/en unknown
- 2017-09-15 AU AU2017325983A patent/AU2017325983B2/en active Active
- 2017-09-15 BR BR112019005179-1A patent/BR112019005179A2/pt unknown
- 2017-09-15 CN CN202311187493.XA patent/CN117192130A/zh active Pending
- 2017-09-15 KR KR1020197010801A patent/KR102513485B1/ko active Active
- 2017-09-15 MX MX2019002932A patent/MX2019002932A/es unknown
- 2017-09-15 WO PCT/US2017/051749 patent/WO2018053244A1/en not_active Ceased
- 2017-09-15 KR KR1020257015097A patent/KR20250073510A/ko active Pending
-
2019
- 2019-03-13 MX MX2024009782A patent/MX2024009782A/es unknown
- 2019-03-21 CO CONC2019/0002599A patent/CO2019002599A2/es unknown
-
2023
- 2023-02-08 JP JP2023017816A patent/JP7412616B2/ja active Active
- 2023-10-04 US US18/480,709 patent/US20240142468A1/en active Pending
- 2023-12-26 JP JP2023218832A patent/JP7693788B2/ja active Active
-
2024
- 2024-03-07 AU AU2024201506A patent/AU2024201506B2/en active Active
-
2025
- 2025-06-05 JP JP2025094023A patent/JP2025124852A/ja active Pending
-
2026
- 2026-02-19 AU AU2026201253A patent/AU2026201253A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019002607A2 (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto | |
| CO2019002608A2 (es) | Biomarcadores de arn para angioedema hereditario | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| GB2556004A (en) | Markers of stroke and stroke severity | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX2019007653A (es) | Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana. | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| MX387936B (es) | Metodo para la cuantificacion de huevos de parasitos en las heces. | |
| MX2025011654A (es) | Anticuerpos contra alfa sinucleina y usos de los mismos | |
| MX2021001659A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| CR9635A (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente | |
| MX368099B (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| BR112018071583A2 (pt) | métodos para determinar dpp3 e métodos terapêuticos | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| MX2017005888A (es) | Dispositivos, sistemas y metodos para la deteccion de analitos. | |
| CL2019002438A1 (es) | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| BR112019006862A2 (pt) | dispositivo de análise e método para testagem de uma amostra | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| BR112018010764A2 (pt) | método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente | |
| UY37082A (es) | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv | |
| CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto | |
| MX2022002886A (es) | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. | |
| MX2016012278A (es) | Deteccion temprana de preeclampsia. |